Aeris Therapeutics Inc., of Woburn, Mass., received U.S. Patent No

BioMimetic Therapeutics Inc., of Franklin, Tenn., has received Canadian Patent No

Mirna Therapeutics Inc., of Austin, Texas, received a notice of allowance for a patent relating to the therapeutic application of let-7 in the regulation of oncogenes...Trius Therapeutics Inc., of San Diego, received U.S. Patent No

Lorus Therapeutics Inc., of Toronto, received a notice of allowance for a patent covering composition of matter for lead antimicrobial compound LOR-220 and related small molecules

Regulus Therapeutics Inc., of La Jolla, Calif., received a patent related to the Sarnow patent series directed to methods of reducing HCV viral genome amount with an antisense inhibitor of miR-133 in combination with other HCV therapeutic agents

Five Prime Therapeutics Inc., of San Francisco, received U.S. Patent No

Regulus Therapeutics Inc., of Carlsbad, Calif., received a patent covering methods of antagonizing miR-181a to regulate immune response

Viron Therapeutics Inc., of London, Ontario, was granted U.S. Patent No

Fate Therapeutics Inc., of San Diego, was issued a patent titled "Methods for Reprogramming Somatic Cells," which covers foundational induced pluripotent stem cell technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics

Allos Therapeutics Inc., of Westminster, Colo., received U.S. Patent No

Regulus Therapeutics Inc., of Carlsbad, Calif., received a patent within the Esau patent estate covering methods of inhibiting miR-122, a liver-specific microRNA that has been shown to facilitate replication of hepatitis C virus infection

Kylin Therapeutics Inc., of West Lafayette, Ind., received a notice of allowance for a patent broadly covering a number of functionalities for its lead technology platform, "packaging RNA," such as receptor binding, ribozyme activity and RNA interference

Allon Therapeutics Inc., of Vancouver, British Columbia, received a patent covering the chemical composition of two component peptides and their use in drugs to protect brain cells from degenerative diseases

Amicus Therapeutics Inc., of Cranbury, N.J., received U.S. Patent No...Cytori Therapeutics Inc., of San Diego, received a notice of allowance on a patent to broad protection of its Celution System

Orexigen Therapeutics Inc., of San Diego, was issued its "Weber/Cowley methods patent" (U.S. Patent No. 7,462,626), which covers methods of treating obesity with combinations of bupropion and naltrexone, the two active agents in Orexigen's lead drug, Contrave

Advaxis Inc., of North Brunswick, N.J., said the European Patent Court in Munich, Germany, ruled for Advaxis and against Anza Therapeutics Inc., of Concord, Calif., (formerly Cerus Corp.) regarding a patent covering the use of bacteria to deliver an antigen and generate an anti-tumor immune response, which relates to Advaxis' clinical-stage oncology drug, Lovaxin C

BioMimetic Therapeutics Inc., of Franklin, Tenn., was granted a patent application titled "Platelet-Derived Growth Factor Compositions and Methods of Use Thereof

Orexigen Therapeutics Inc., of San Diego, received a notice of allowance for the "Weber/Cowley methods patent," which provides coverage for Contrave, its lead obesity drug comprised of bupropion and naltrexone

Agile Therapeutics Inc., of Princeton, N.J., was issued U.S. Patent Nos...Cytori Therapeutics Inc., of San Diego, was granted U.S. Patent No